Zacks: Brokerages Anticipate Inspire Medical Systems (NYSE:INSP) Will Announce Earnings of -$0.43 Per Share

Share on StockTwits

Wall Street analysts forecast that Inspire Medical Systems (NYSE:INSP) will report earnings per share of ($0.43) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Inspire Medical Systems’ earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.48). Inspire Medical Systems reported earnings per share of ($0.22) in the same quarter last year, which would suggest a negative year-over-year growth rate of 95.5%. The business is scheduled to report its next earnings report after the market closes on Tuesday, November 5th.

On average, analysts expect that Inspire Medical Systems will report full-year earnings of ($1.55) per share for the current fiscal year, with EPS estimates ranging from ($1.65) to ($1.40). For the next fiscal year, analysts expect that the company will report earnings of ($1.61) per share, with EPS estimates ranging from ($1.87) to ($1.27). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Inspire Medical Systems.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.13. Inspire Medical Systems had a negative return on equity of 17.75% and a negative net margin of 39.73%. The firm had revenue of $18.03 million for the quarter, compared to the consensus estimate of $21.26 million. During the same quarter in the prior year, the business earned ($0.43) EPS. The business’s revenue for the quarter was up 64.9% compared to the same quarter last year.

Several research firms have issued reports on INSP. Dougherty & Co set a $78.00 price objective on Inspire Medical Systems and gave the stock a “buy” rating in a report on Friday, September 27th. Bank of America reaffirmed a “neutral” rating and set a $75.00 price objective (up previously from $65.00) on shares of Inspire Medical Systems in a report on Monday, July 8th. Finally, Zacks Investment Research downgraded Inspire Medical Systems from a “buy” rating to a “hold” rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Inspire Medical Systems currently has a consensus rating of “Hold” and an average price target of $60.00.

In other Inspire Medical Systems news, CEO Timothy P. Herbert sold 5,000 shares of the stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $66.14, for a total transaction of $330,700.00. Also, Director Marilyn C. Nelson sold 60,000 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $66.71, for a total value of $4,002,600.00. In the last three months, insiders sold 172,490 shares of company stock worth $11,511,224. 12.10% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the business. Macquarie Group Ltd. boosted its stake in shares of Inspire Medical Systems by 57.5% during the 2nd quarter. Macquarie Group Ltd. now owns 126,041 shares of the company’s stock worth $7,644,000 after buying an additional 46,026 shares during the last quarter. MetLife Investment Advisors LLC boosted its stake in shares of Inspire Medical Systems by 20.7% during the 1st quarter. MetLife Investment Advisors LLC now owns 6,838 shares of the company’s stock worth $388,000 after buying an additional 1,175 shares during the last quarter. Strs Ohio boosted its stake in shares of Inspire Medical Systems by 8.7% during the 2nd quarter. Strs Ohio now owns 2,500 shares of the company’s stock worth $151,000 after buying an additional 200 shares during the last quarter. Atika Capital Management LLC lifted its stake in Inspire Medical Systems by 18.7% in the 2nd quarter. Atika Capital Management LLC now owns 165,000 shares of the company’s stock valued at $10,007,000 after purchasing an additional 26,000 shares during the last quarter. Finally, Honkamp Krueger Financial Services Inc. acquired a new stake in Inspire Medical Systems in the 2nd quarter valued at about $228,000. Hedge funds and other institutional investors own 82.94% of the company’s stock.

NYSE:INSP traded up $0.36 during trading hours on Friday, hitting $55.25. 400 shares of the stock were exchanged, compared to its average volume of 279,944. The company’s 50 day moving average is $61.86 and its two-hundred day moving average is $59.50. Inspire Medical Systems has a twelve month low of $35.43 and a twelve month high of $71.71. The company has a quick ratio of 20.05, a current ratio of 20.46 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $1.32 billion, a P/E ratio of -36.77 and a beta of 1.24.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

Read More: What is Forex?

Get a free copy of the Zacks research report on Inspire Medical Systems (INSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inspire Medical Systems (NYSE:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Rosehill Resources Inc  Major Shareholder Sells $28,750.00 in Stock
Rosehill Resources Inc Major Shareholder Sells $28,750.00 in Stock
Zacks: Brokerages Anticipate Mobileiron Inc  Will Post Earnings of $0.04 Per Share
Zacks: Brokerages Anticipate Mobileiron Inc Will Post Earnings of $0.04 Per Share
OptiNose  Upgraded to Hold at Zacks Investment Research
OptiNose Upgraded to Hold at Zacks Investment Research
Provention Bio  Downgraded by Zacks Investment Research
Provention Bio Downgraded by Zacks Investment Research
RadNet  Rating Lowered to Hold at Zacks Investment Research
RadNet Rating Lowered to Hold at Zacks Investment Research
Weekly Research Analysts’ Ratings Changes for Rocket Pharmaceuticals
Weekly Research Analysts’ Ratings Changes for Rocket Pharmaceuticals


© 2006-2019 Ticker Report